Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Нейробластома

Список литературы

  1. Berthold F., Hero B. Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach // Drugs. Adis International Ltd, 2000. Vol. 59, № 6. P. 1261-1277.
  2. Berthold F., Simon T. Clinical presentation // Neuroblastoma. 2005. P. 63-86.
  3. Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma // Nature Reviews Cancer. 2003. Vol. 3, № 3. P. 203-216.
  4. Narod S.A., Lenoir G.M., Stiller C. An estimate of the heritable fraction of childhood cancer // Br. J. Cancer. 1991. Vol. 63, № 6. P. 993-999.
  5. Ambros P.F. et al. International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee // British Journal of Cancer. 2009. Vol. 100, № 9. P. 1471-1482.
  6. J.G. G. et al. Infant cancer in the U.S.: Histology-specific incidence and trends, 1973 to 1992 // J. Pediatr. Hematol. Oncol. 1997. Vol. 19, № 5. P. 428-432.
  7. Kaatsch P., Spix C. German Childhood Cancer Registry - Annual Report 2015 (1980-2014) Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz. 2015. 118 p.
  8. Tulla M. et al. Incidence, trends, and survival of children with embryonal tumors // Pediatrics. American Academy of Pediatrics, 2015. Vol. 136, № 3. P. e623-e632.
  9. Brodeur G.M. et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma // J. Clin. Oncol. 1988. Vol. 6, № 12. P. 1874-1881.
  10. Monclair T. et al. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report // J. Clin. Oncol. 2009. Vol. 27, № 2. P. 298-303.
  11. Brisse H.J. et al. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the international neuroblastoma risk group project // Radiology. 2011. Vol. 261, № 1. P. 243-257.
  12. Brodeur G.M. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment // J. Clin. Oncol. Lippincott Williams and Wilkins, 1993. Vol. 11, № 8. P. 1466-1477.
  13. Berthold F. NB2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma Principal investigator [Electronic resource]. 2004. URL: http://nodgo.org/sites/default/files/protokol_neuroblastoma-1.pdf (accessed: 12.12.2019).
  14. Детская онкология. Национальное руководство. Под ред. М.Д. Алиева, В.Г. Полякова, Г.Л. Менткевича, С.А. Маяковой. М.: Издательская группа РОНЦ. Практическая медицина, 2012. 684 p.
  15. Варфоломеева С.Р. Нейробластома // Педиатрия. Национальное руководство в 2 томах. Под редакцией А.А. Баранова. 2009.
  16. Wolmer-Solberg N. et al. Frequent detection of human cytomegalovirus in neuroblastoma: A novel therapeutic target? // Int. J. Cancer. 2013. Vol. 133, № 10. P. 2351-2361.
  17. Nissim I. et al. Ifosfamide-induced nephrotoxicity: Mechanism and prevention // Cancer Res. 2006. Vol. 66, № 15. P. 7824-7831.
  18. Xia J. et al. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis // J. Huazhong Univ. Sci. Technol. - Med. Sci. 2017. Vol. 37, № 5. P. 649-660.
  19. Piccardo A. et al. PET/CT imaging in neuroblastoma. // Q. J. Nucl. Med. Mol. Imaging. 2013. Vol. 57, № 1. P. 29-39.
  20. Shimada H. et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. // Cancer. 2001. Vol. 92, № 9. P. 2451-2461.
  21. Madabhavi I. et al. A study of the use of peripherally inserted central catheters in cancer patients: A single-center experience // J. Vasc. Nurs. Mosby Inc., 2018. Vol. 36, № 3. P. 149-156.
  22. Rykov M.Y. et al. Peripherally inserted central catheters in the treatment of children with cancer: Results of a multicenter study // J. Vasc. Access. SAGE Publications Ltd, 2018. Vol. 19, № 4. P. 378-381.
  23. van den Bosch C.H. et al. Incidence, severity and outcome of central line related complications in pediatric oncology patients; A single center study // J. Pediatr. Surg. W.B. Saunders, 2019. Vol. 54, № 9. P. 1894-1900.
  24. Whittle S.B., Williamson K.C., Russell H. V. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma // Pediatr. Hematol. Oncol. Taylor and Francis Ltd, 2017. Vol. 34, № 5. P. 331-342.
  25. Devrim I. et al. A single center’s experience with Candida parapsilosis related long-term central venous access device infections: The port removal decision and its outcomes // Pediatr. Hematol. Oncol. Informa Healthcare, 2014. Vol. 31, № 5. P. 435-441.
  26. Berthold F. et al. Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015 // Pediatr. Drugs. Springer International Publishing, 2017. Vol. 19, № 6. P. 577-593.
  27. Gupta M., Dhasmana A. Radiation Therapy in Metastatic Neuroblastoma // Nuclear Medicine Physics. IntechOpen, 2019.
  28. Boztug K. et al. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment // Pediatr. Blood Cancer. 2006. Vol. 46, № 2. P. 253-257.
  29. McGahren E.D., Rodgers B.M., Waldron P.E. Successful management of stage 4S neuroblastoma and severe hepatomegaly using absorbable mesh in an infant. // J. Pediatr. Surg. 1998. Vol. 33, № 10. P. 1554-1557.
  30. Roberts S. et al. Unique management of stage 4S neuroblastoma complicated by massive hepatomegaly: Case report and review of the literature // Am. J. Pediatr. Hematol. Oncol. 2002. Vol. 24, № 2. P. 142-144.
  31. Reynolds C.P. et al. Retinoid therapy of high-risk neuroblastoma // Cancer Letters. Elsevier Ireland Ltd, 2003. Vol. 197, № 1-2. P. 185-192.
  32. Курникова Е.Е. et al. Результаты мобилизации, афереза и аутореинфузии гемопоэтических стволовых клеток у детей с нейробластомой: роль мониторинга количества CD34+ клеток в периферической крови // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017. Vol. 16, № 1. P. 28-39.
  33. Ladenstein R. et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2017. Vol. 18, № 4. P. 500-514.
  34. Berthold F. et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial // Lancet Oncol. 2005. Vol. 6, № 9. P. 649-658.
  35. Granger M. et al. Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study. // J. Clin. Oncol. American Society of Clinical Oncology (ASCO), 2016. Vol. 34, № 15_suppl. P. 10528-10528.
  36. Proust-Houdemont S. et al. Busulfan-melphalan in high-risk neuroblastoma: The 30-year experience of a single institution // Bone Marrow Transplant. Nature Publishing Group, 2016. Vol. 51, № 8. P. 1076-1081.
  37. Matthay K.K. et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children’s oncology group study // J. Clin. Oncol. 2009. Vol. 27, № 7. P. 1007-1013.
  38. Simon T. et al. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease // Strahlentherapie und Onkol. Springer, 2006. Vol. 182, № 7. P. 389-394.
  39. August D.A., Huhmann M.B. A.S.P.E.N. Clinical guidelines: Nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation // Journal of Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr, 2009. Vol. 33, № 5. P. 472-500.
  40. Васильева Е.С., Вашура А.Ю., Литвинов Д.В. Нутритивный статус детей с онкологическими и гематологическими заболеваниями, находящихся на лечении в ФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачева» (результаты скринингового исследования) // Современная онкология. 2016. Vol. 18, № 4. P. 48-52.
  41. Isenring E., Elia M. Which screening method is appropriate for older cancer patients at risk for malnutrition? // Nutrition. Elsevier Inc., 2015. Vol. 31, № 4. P. 594-597.
  42. Martin L. et al. Diagnostic criteria for the classification of cancer-associated weight loss // J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, № 1. P. 90-99.
  43. Manary M.J., Sandige H.L. Management of acute moderate and severe childhood malnutrition // BMJ. BMJ, 2008. Vol. 337, № 7680. P. 1227-1230.
  44. van den Broeck J., Eeckels R., Massa G. Validity of Single-Weight Measurements to Predict Current Malnutrition and Mortality in Children // J. Nutr. 1996. Vol. 126, № 1. P. 113-120.
  45. Meijers J.M.M. et al. Nutritional care; do process and structure indicators influence malnutrition prevalence over time? // Clin. Nutr. Churchill Livingstone, 2014. Vol. 33, № 3. P. 459465.
  46. Muscaritoli M. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “ cachexia-anorexia in chronic wasting diseases” and “ nutrition in geriatrics” // Clin. Nutr. Clin Nutr, 2010. Vol. 29, № 2. P. 154-159.
  47. Kondrup J. et al. ESPEN guidelines for nutrition screening 2002 // Clin. Nutr. Churchill Livingstone, 2003. Vol. 22, № 4. P. 415-421.
  48. Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11-48.
  49. Joosten K.F.M., Kerklaan D., Verbruggen S.C.A.T. Nutritional support and the role of the stress response in critically ill children // Current Opinion in Clinical Nutrition and Metabolic Care. Lippincott Williams and Wilkins, 2016. Vol. 19, № 3. P. 226-233.
  50. Koletzko B. et al. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatri // Journal of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr, 2005. Vol. 41, № SUPPL. 2. 87 p.
  51. Tanner L. et al. Cancer Rehabilitation in the Pediatric and Adolescent/Young Adult Population // Seminars in Oncology Nursing. Elsevier Inc, 2020. Vol. 36, № 1. P. 150984.
  52. Солопова Г.Г. et al. Организация службы инфекционного контроля в клинике детской гематологии/онкологии. Педиатрия Онкогематология № 10 (111) / 2015 // Доктор.Ру. 2015. Vol. 111, № 10. P. 14-22.
  53. Prasad P., Nania J.J., Shankar S.M. Pneumocystis pneumonia in children receiving chemotherapy // Pediatr. Blood Cancer. 2008. Vol. 50, № 4. P. 896-898.
  54. Качанов Д.Ю. et al. Диспансерное наблюдение за пациентами с нейробластомой группы низкого риска (за исключением 4S стадии) // Российский журнал детской гематологии и онкологии. 2015. Vol. 2 № 1. P. 101-106.
  55. Bansal D. et al. Management of Neuroblastoma: ICMR Consensus Document // Indian J. Pediatr. Springer India, 2017. Vol. 84, № 6. P. 446-455.
  56. Park J.R., Eggert A., Caron H. Neuroblastoma: Biology, Prognosis, and Treatment // Hematology/Oncology Clinics of North America. 2010. Vol. 24, № 1. P. 65-86.
  57. De Bernardi B. et al. Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects // Cancer Letters. 2005. Vol. 228, № 1-2. P. 283-299.
  58. Papavramidis T.S. et al. Abdominal compartment syndrome - Intra-abdominal hypertension: Defining, diagnosing, and managing // Journal of Emergencies, Trauma and Shock. 2011. Vol. 4, № 2. P. 279-291.
  59. Вагнер К.Э. Об изменении внутрибрюшного давления при различных условиях // Врач. Vol. 9 №12. P. 233.
  60. Хрипун А.И. et al. Синдром интраабдоминальной гипертензии. История и современное состояние вопроса // Acta Biomed. Sci. 2010. Vol. 3. P. 374-378.
  61. Fietsam R. et al. Intra-abdominal compartment syndrome as a complication of ruptured abdominal aortic aneurysm repair // Am. Surg. 1989. Vol. 55, № 6. P. 396-402.
  62. Kron I.L., Harman P.K., Nolan S.P. The measurement of intra-abdominal pressure as a criterion for abdominal re-exploration // Ann. Surg. 1984. Vol. 199, № 1. P. 28-30.
  63. Patel A. et al. Abdominal compartment syndrome // American Journal of Roentgenology. 2007. Vol. 189, № 5. P. 1037-1043.
  64. Гареев Р.Н. et al. Интраабдоминальная гипертензия // Медицинский вестник Башкортостана. 2012. Vol. 7 (4). P. 66-73.
  65. Nelson R.L. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer // Med. Pediatr. Oncol. 1982. Vol. 10, № 2. P. 115-127.
  66. Nelson R.L., Dyke R.W., Root M.A. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer // Cancer Treat. Rev. Elsevier, 1980. Vol. 7, № SUPPL. 1. P. 17-24.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*